Allogene Therapeutics (NASDAQ:ALLO) PT Lowered to $7.50
Allogene Therapeutics (NASDAQ:ALLO – Get Rating) had its price target reduced by Stifel Nicolaus from $8.00 to $7.50 in a research note released on Thursday, The Fly reports. Several other research analysts also recently commented on ALLO. Robert W. Baird raised shares of Allogene Therapeutics from a neutral rating to an outperform rating and set […]